Evidence map›Paper›PMID 34767139›Full record

ReviewClinical & experimental metastasis2022

Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels.

Stanley P Leong, Kamila Naxerova, Laura Keller, Klaus Pantel, Marlys Witte

Open access · hybridAbstract readReview
In one paragraph

Review in Clinical & experimental metastasis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
6.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 104 citations in OpenAlex.

  1. Urothelial Carcinoma in a Cat with Bilateral Ectopic Ureters.Animals : an open access journal from MDPI · 2026
    Article
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Observational
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Stanley P LeongCalifornia Pacific Medical Center and Research Institute, San Francisco, CA, USA. leongsx@sutterhealth.org.ORCID 0000-0002-0047-0112
Kamila NaxerovaCenter for Systems Biology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Laura KellerInstitute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Klaus PantelInstitute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Marlys WitteDepartment of Surgery, Neurosurgery and Pediatrics, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.
Universität Hamburg · DEHarvard University · USSutter Health · USUniversity of Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer metastasis is the process by which primary cancer cells invade through the lymphatic or blood vessels to distant sites. The molecular mechanisms by which cancer cells spread either through the lymphatic versus blood vessels or both are not well established. Two major developments have helped us to understand the process more clearly. First, the development of the sentinel lymph node (SLN) concept which is well established in melanoma and breast cancer. The SLN is the first lymph node in the draining nodal basin to receive cancer cells. Patients with a negative SLN biopsy show a significantly lower incidence of distant metastasis, suggesting that the SLN may be the major gateway for cancer metastasis in these cancer types. Second, the discovery and characterization of several biomarkers including VEGF-C, LYVE-1, Podoplanin and Prox-1 have opened new vistas in the understanding of the induction of lymphangiogenesis by cancer cells. Cancer cells must complete multiple steps to invade the lymphatic system, some of which may be enabled by the evolution of new traits during cancer progression. Thus, cancer cells may spread initially through the main gateway of the SLN, from which evolving cancer clones can invade the blood vessels to distant sites. Cancer cells may also enter the blood vessels directly, bypassing the SLN to establish distant metastases. Future studies need to pinpoint the molecules that are used by cancer cells at different stages of metastasis via different routes so that specific therapies can be targeted against these molecules, with the goal of stopping or preventing cancer metastasis.

Indexed as

Lymphatic VesselsMelanomaHumansLymphatic MetastasisLymphatic SystemLymph NodesSentinel Lymph Node BiopsyCancer metastasisCancer metastasis through the blood vesselsCancer metastasis through the lymphatic vessels

Identifiers

PMID34767139
PMCPMC8967809
OpenAlexW3214679898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.